IQVIQVIA HOLDINGS INC.
Services-Commercial Physical & Biological Research
- Revenue
- $16.3B
- 5.9% YoY
- Operating margin
- 13.4%
- 6.4% YoY
- EBITDA
- $3.3B
- 0.3% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 1.8×
- $6.0B net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear195% of net incomeCash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear68% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyFired55% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $13.9B | $14.4B | $15.0B | $15.4B | $16.3B | 5.9% |
| Operating income | $1.4B | $1.8B | $2.0B | $2.2B | $2.2B | 0.9% |
| Net income | $966M | $1.1B | $1.4B | $1.4B | $1.4B | 0.9% |
| Operating cash flow | $2.9B | $2.3B | $2.1B | $2.7B | $2.7B | 2.3% |
| Capex | $640M | $674M | $649M | $602M | $603M | 0.2% |
| Stock-based comp | $170M | $194M | $217M | $206M | $247M | 20% |
| Buybacks | $406M | $1.2B | $992M | $1.4B | $1.2B | 7.9% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $697K · 1
- Net
- −$697K
Pay vs performance
No pay-versus-performance disclosure yet.